Oncolytics Biotech® Announces Publication Demonstrating Pelareorep Creates Immune Responses in Liver Cancer That Make Tumors Susceptible to Immunotherapy

Oncolytics Biotech (ONCY) reported preclinical findings in PNAS showing pelareorep treatment may alter the tumor microenvironment in liver cancer, increasing PD-L1 and ICOSL levels, and CD8+ T-cell density. The company noted liver cancer is not a target indication but is studying pelareorep in colorectal cancer with an interim update expected by year-end 2026. ONCY stock closed at $0.67, down 2.05% in premarket.

ONCOLYTICS BIOTECH INC (ONCY) filed an SEC Form 8-K — Other Events. Oncolytics Biotech ® Announces Publication Demonstrating Pelareorep Creates Immune Responses in Liver Cancer That Make Tumors Susceptible to Immunotherapy Data support pelareorep’s potential as a backbone therapy to transform immunologically inactive liver tumors into a phenotype

ONCOLYTICS BIOTECH INC (ONCY) filed an SEC Form 8-K — Other Events. Oncolytics Biotech ® Reports Accelerating Enrollment in Randomized REO 033 RAS-Mutant, MSS Colorectal Cancer Study Substantially all planned REO 033 clinical sites are now activated, with multiple patients currently on study Company expects to have sufficient Part A data to provi

Johnson & Johnson (JNJ) received CE Marking for ACUVUE OASYS MAX 2-Week contact lenses. GSK (GSK) expanded Shingrix approval in Japan. Axogen (AXGN) to acquire BioCircuit for $200M. Femasys (FEMY) partnered with CapexMD for fertility financing. EpilepsyGTx collaborated with Viralgen (BAYN.DE) for gene therapy. HCW Biologics (HCWB) partnered with Akron Biotech. Bluejay Diagnostics (BJDX) teamed with Lovell for federal market access. Transgene (TNG.PA) expanded partnership with ProBioGen. Oncolyti

Oncolytics Biotech (ONCY) reported positive preclinical results for pelareorep combined with a pan-RAS inhibitor in colorectal cancer. The combination reduced tumor growth, with the greatest reductions in the RAS inhibitor and combination groups. The company plans to expand preclinical evaluation, aiming to characterize pelareorep's impact on tumor response and resistance development. Pelareorep is an investigational immunotherapy with a dual mechanism of action.

Oncolytics Biotech (ONCY) said the U.S. FDA provided written feedback aligning the registrational path for its REO 033 study of pelareorep in second-line RAS-mutant, MSS metastatic colorectal cancer. The FDA supports expanding into a pivotal Part B, with accelerated approval possible via ORR and DoR, and PFS for full approval. ONCY plans an End-of-Phase 2 meeting. Shares trade at $0.83.